Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00540293 |
To evaluate the percentage of Korean dyslipidemic subjects in the total group and each cardiovascular risk group achieving LDL-C target as defined by NCEP ATP Ⅲ criteria at starting doses of 10mg, 20mg and 40mg of atorvastatin after 8 weeks of treatment.
Condition | Intervention | Phase |
---|---|---|
Dyslipidemias |
Drug: Atorvastatin |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Multicenter, Eight-Week Treatment, Single-Step Titration Open-Label Study Assessing The Percentage Of Korean Dyslipidemic Patients Achieving LDL Cholesterol Target With Atorvastatin Starting Doses Of 10 MG, 20 MG, And 40 MG. |
Enrollment: | 416 |
Study Start Date: | October 2007 |
Study Completion Date: | May 2008 |
Primary Completion Date: | May 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Treatment group: Experimental
this patient group consists of dyslipidemia patients with various CVD risk factors
|
Drug: Atorvastatin
Prescription of 10/20/40mg dose atorvastatin based the personal risk factor that is defined in the NCEP ATP III guideline in a single patient group
|
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Korea, Republic of | |
Pfizer Investigational Site | |
Seoul, Korea, Republic of, 137-701 | |
Pfizer Investigational Site | |
Seoul, Korea, Republic of, 110-744 | |
Pfizer Investigational Site | |
Seoul, Korea, Republic of, 136-705 | |
Pfizer Investigational Site | |
Gyeonggi-do, Korea, Republic of, 463-707 | |
Pfizer Investigational Site | |
Seoul, Korea, Republic of, 120-752 | |
Pfizer Investigational Site | |
Gwangju, Korea, Republic of, 501-757 | |
Pfizer Investigational Site | |
Seoul, Korea, Republic of, 143-914 | |
Pfizer Investigational Site | |
Incheon, Korea, Republic of, 405-760 | |
Pfizer Investigational Site | |
Daejeon, Korea, Republic of, 302-718 | |
Pfizer Investigational Site | |
Seoul, Korea, Republic of, 110-746 | |
Pfizer Investigational Site | |
Gwangju, Korea, Republic of, 503-715 | |
Pfizer Investigational Site | |
SEOUL, Korea, Republic of, 138-736 | |
Pfizer Investigational Site | |
Daegu, Korea, Republic of, 700-712 | |
Pfizer Investigational Site | |
Busan, Korea, Republic of, 602-739 | |
Pfizer Investigational Site | |
Busan, Korea, Republic of, 614-735 | |
Pfizer Investigational Site | |
Seoul, Korea, Republic of, 134-010 | |
Pfizer Investigational Site | |
Gyeonggi-do, Korea, Republic of, 431-070 | |
Pfizer Investigational Site | |
Kyunggi-do, Korea, Republic of, 420-717 | |
Korea, Republic of, Korea | |
Pfizer Investigational Site | |
Seoul, Korea, Korea, Republic of, 135-710 | |
Pfizer Investigational Site | |
Daegu, Korea, Korea, Republic of, 705-717 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | A2581157 |
Study First Received: | October 4, 2007 |
Last Updated: | June 3, 2008 |
ClinicalTrials.gov Identifier: | NCT00540293 |
Health Authority: | Korea: Institutional Review Board |
Metabolic Diseases Metabolic disorder Atorvastatin Dyslipidemias Lipid Metabolism Disorders |
Antimetabolites Molecular Mechanisms of Pharmacological Action Therapeutic Uses Antilipemic Agents |
Enzyme Inhibitors Anticholesteremic Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Pharmacologic Actions |